Last updated: May 31, 2026
Executive summary
ZYPITAMAG is not a generic, active-ingredient identifier, and no supplier-manufacturer sourcing map can be produced from the information provided. A complete, accurate supplier list requires ZYPITAMAG’s FDA-established name (including dosage form/strength), label holder, and the specific listed manufacturers (drug substance and finished dosage) tied to the product’s regulatory records and official listings.
What companies supply ZYPITAMAG (finished dosage and active ingredient)?
A supplier list depends on how ZYPITAMAG is registered and marketed in the applicable jurisdiction. For prescription drug products, “supplier” typically maps to:
- Marketing authorization holder or labeler (often aligned with the NDA/BLA holder)
- Finished dosage manufacturing sites (tablet/capsule/liquid fill-finish)
- Drug substance manufacturers (API site(s), if separate)
- Repackagers/distributors (if used)
Without ZYPITAMAG’s dossier-level identity (NDA/BLA number, strength/dosage form, route of administration, and active ingredient), there is no reliable basis to name specific manufacturers or sourcing companies.
How do “labeler,” “manufacturer,” and “distributor” differ for ZYPITAMAG?
- Labeler: entity responsible for product labeling and regulatory compliance.
- Manufacturer: site(s) and legal entities producing the drug product and/or API.
- Distributor: entity handling warehousing and logistics; may not manufacture.
Which supplier sources usually appear in official drug listings?
- FDA Orange Book (NDC, labeler, applicants, patent holders, dosage form)
- FDA drug establishment listings (manufacturing and processing sites)
- Site-specific cGMP registrations for API and finished dosage
What patents protect ZYPITAMAG and how does that affect supplier access?
Supplier access is constrained by:
- Composition-of-matter and method-of-use patents (API and therapeutic use)
- Formulation/process patents (excipients, release profiles, manufacturing)
- Regulatory exclusivities (NCE, exclusivity under Hatch-Waxman)
No patent estate or exclusivity timeline can be linked to ZYPITAMAG without its active ingredient and specific FDA approval record.
What is the Orange Book status of ZYPITAMAG?
Orange Book status requires:
- Correct active ingredient and drug product identifier
- Match to NDC and dosage form
With no identifiable FDA product record, Orange Book listings cannot be enumerated.
When does ZYPITAMAG lose exclusivity and open generic or 505(b)(2) supply?
Generic and 505(b)(2) timelines depend on:
- Patent expirations by listed patent number
- Exclusivity end dates
- Litigation or settlement triggering potential design-arounds
No exclusivity end date can be calculated without the NDA/BLA and the listed patents/exclusivities tied to the product.
Are there Paragraph IV or biosimilar challenges for ZYPITAMAG?
This question is answered via:
- FDA Orange Book challenge listings and litigation dockets
- Court filings for Paragraph IV cases
- For biologics, BLA exclusivity and biosimilar reference product mapping
No challenge profile is possible without the underlying active ingredient and regulatory reference product.
What formulations are protected for ZYPITAMAG (tabs, caps, ER/IR, etc.)?
Formulation scope is typically reflected in:
- Orange Book patent claims to specific dosage forms (IR vs ER, specific salt forms, release mechanisms)
- Manufacturing method patents affecting process conditions
No formulation claims can be attributed to ZYPITAMAG without a defined product and active ingredient.
Which generic or alternative suppliers could enter ZYPITAMAG if IP expires?
Entry scenarios require:
- Correct product identity (strength/route)
- Patent-by-patent landscape
- Manufacturing and formulation feasibility
- Likely 505(b)(2) vs ANDA pathways
A supplier shortlist is not possible without the product’s regulatory and patent record.
How strong is the patent estate for ZYPITAMAG vs competing drugs in the same class?
Strength scoring depends on:
- Number and breadth of unexpired patents
- Claim scope (API, formulation, method-of-use)
- Litigation history
No comparative IP strength can be computed without ZYPITAMAG’s active ingredient and patent list.
Key Takeaways
- A defensible supplier list for ZYPITAMAG cannot be produced without the product’s specific FDA-registered identity (active ingredient, dosage form/strength, and regulatory record).
- Supplier mapping normally comes from official listings that tie labeler and manufacturing sites to an NDC and NDA/BLA.
- Patent and exclusivity status governs which suppliers can source or launch alternatives, but requires a defined patent estate for the specific ZYPITAMAG product.
FAQs
- How can I identify the labeler and manufacturing sites for ZYPITAMAG from official FDA listings?
- What NDC-level details are required to map ZYPITAMAG to API and finished dosage manufacturers?
- How do formulation and process patents block specific alternative suppliers for branded drugs like ZYPITAMAG?
- Where do I find Paragraph IV challenge information linked to ZYPITAMAG product listings?
- What documentation best supports supplier due diligence for pharmaceutical drug sourcing in the ZYPITAMAG supply chain?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Establishment Registration and Drug Listing (Drugs/Facilities). https://www.fda.gov/drugs/drug-establishments/drug-establishment-registration-and-drug-listing
